adagrasib,Pembrolizumab
mirati,merck
['pembro', 'meru', 'krystal-1', 'krystal-7', 'nsclc', 'ca,022,i', 'sclc', 'adagrasib', 'mirati']
data shown for pts enrolled for 6m on krystal-7. rr in this cohort was 56%. overall, high response rates and reassuring safety signals. planning phase iii studies of adagrasib + pembrolizumab vs standard io or chemo-io. homerun? not quite yet, in my opinion. #esmoimmuno22 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown, Host Official @IASLC Podcast #LCSM #HereWeGo #ITYSL